Background: Our objective was to provide consensus recommendations on the optimal management of the immune-mediated inflammatory diseases (IMIDs) seen in patients with spondyloarthritis (SpA) using a multidisciplinary approach, and to develop a simple tool to help earlier recognition and referral of coexisting IMIDs in patients who already have one type of IMID.
Methods: A total of 28 experts in the multidisciplinary management of the SpA-associated IMIDs assessed two questionnaires: one with statements focused on the multidisciplinary management of IMIDs, and a second questionnaire focused on questions useful for early recognition and referral. Panelists assessed the statements with a 9-point ordinal scale (1 = strongly disagree, 9 = strongly agree) using a modified Delphi methodology.
Results: Consensus was reached on 72 out of the 82 statements (87.8%). Panelists agreed that the multidisciplinary approach to IMIDs is not sufficiently developed. The creation of multidisciplinary IMID units might be necessary. These units might focus primarily on patients with two or more coexisting IMIDs, or on IMIDs that are especially complex from a diagnostic or therapeutic point of view. Specialists who attend to patients with IMIDs should perform a screening for other coexisting IMIDs. A simple tool to help earlier recognition and referral of coexisting IMIDs is proposed.
Conclusions: There is a need to improve care for patients with SpA-associated IMIDs. We provide expert recommendations to guide the adoption of a multidisciplinary approach for these cases, and a simple tool that may be useful for earlier recognition of coexisting IMIDs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016300 | PMC |
| http://dx.doi.org/10.1177/2040622320904295 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Coexisting autoimmune disorders among patients with inflammatory bowel disease at a tertiary center in Saudi Arabia: A cross-sectional study.
Saudi J Gastroenterol
January 2025
Department of Gastroenterology and Hepatology, King Fahad Medical City, Riyadh, Saudi Arabia.
Background: Approximately 25% of individuals with inflammatory bowel disease (IBD) concurrently experience immune-mediated inflammatory diseases (IMIDs), while the overall prevalence of these conditions in the general population is 5-7%. Individuals with IBD and concurrent IMIDs tend to have a more aggressive disease profile. We aimed to assess the prevalence of coexisting autoimmune disorders among patients with IBD and their association with inflammatory bowel disease type.
View Article and Find Full Text PDFDo patients with inflammatory bowel disease really know what other immune-mediated inflammatory diseases they are diagnosed with?
J Crohns Colitis
July 2024
Gastroenteroloy Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
Article Synopsis
- Researchers wanted to see how much people with inflammatory bowel disease (IBD) understood about other similar diseases they might have at the same time.
- They had 1,620 people fill out a questionnaire about 54 immune-related diseases and then checked their medical records to see if what they said was correct.
- They found that while many patients had other diseases, most didn't know about them well, especially those affecting bones and joints.
Tracking Cardiovascular Comorbidity in Models of Chronic Inflammatory Disease.
Methods Mol Biol
June 2023
School of Cellular and Molecular Medicine, Biomedical Sciences Building, University of Bristol, Bristol, UK.
Immune-mediated inflammatory diseases (IMIDs) are commonly associated with complex coexisting conditions, and cardiovascular comorbidities are a common cause of mortality in systemic inflammation. Experimental models of disease provide an opportunity to dissect inflammatory mechanisms that promote damage to vascular tissues affected by comorbidity. Here, we describe methods to recover the thoracic aorta from mice during experimental inflammatory arthritis and assess vascular constriction responses by isometric tension myography.
View Article and Find Full Text PDFAcquired B-cell deficiency secondary to B-cell-depleting therapies.
J Immunol Methods
December 2022
Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, OH, USA. Electronic address:
The advantage of the newer biological therapies is that the immunosuppressive effect is targeted, in contrast, to the standard, traditional immunomodulatory agents, which have a more global effect. However, there are unintended targets and consequences, even to these "precise" therapeutics, leading to acquired or secondary immunodeficiencies. Besides depleting specific cellular immune subsets, these biological agents, which include monoclonal antibodies against biologically relevant molecules, often have broader functional immune consequences, which become apparent over time.
View Article and Find Full Text PDFInflammatory Bowel Diseases Affect the Phenotype and Disease Course of Coexisting Immune-Mediated Inflammatory Diseases: A Systematic Review With Meta-Analysis.
Inflamm Bowel Dis
November 2022
Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.
Article Synopsis
- Researchers investigated how inflammatory bowel diseases (IBDs) influence the characteristics and severity of co-occurring immune-mediated inflammatory diseases (IMIDs).
- After reviewing 13,220 studies, they focused on 73 that provided insights into IMIDs associated with IBD, specifically looking at conditions like primary sclerosing cholangitis, axial spondyloarthropathies, and psoriasis.
- The analysis revealed that IBD can lead to less severe manifestations of certain IMIDs and specific clinical features, highlighting the need for a multidisciplinary approach in treating patients with these overlapping conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!